To investigate whether ErbB family receptor inhibition could improve the clinical outcome of brain tumor patients, the use of single EGFR/ErbB2 TK inhibitors was analyzed for its anti-tumor activity in various clinical trials. Here, ERBB2 is linked to neoplasm.